Summarized by Masters of Longevity from PR Newswire.
Perioperative use of a prostate cancer drug is examined in a clinical substudy, previewing what readers will learn about its comparison with surgery alone.
Key Takeaways
- Perioperative apalutamide plus ADT reduced recurrence or death risk by sixty-two percent.
- The regimen lowered the risk of metastasis or death by fifty-one percent.
- Patients received six 28-day cycles before surgery and six cycles after surgery.
